Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH W KIM

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1295913531
CMS profile
331552
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$585.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $585.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $585.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH W KIM

NPI 1295913531 · CMS profile ID 331552

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295913531?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295913531?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295913531?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOSEPH W KIM, NPI 1295913531, CMS profile ID 331552, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295913531?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $585.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $585.0006/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788089367 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,478.38 10
PY2020 $3,374.14 4
PY2021 $585.00 1
PY2022 $10,547.28 13
PY2023 $1,967.17 5
PY2024 $155.03 2
PY2025 $212.94 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $314.64 2
PY2025 Principal investigator $1,110,282.24 135
PY2024 Recipient $191.83 1
PY2024 Principal investigator $346,888.51 69
PY2023 Principal investigator $403,164.02 48
PY2022 Principal investigator $107,144.09 26
PY2021 Recipient $1,076.26 1
PY2021 Principal investigator $36,646.51 15
PY2020 Recipient $1,914.15 1
PY2020 Principal investigator $48,418.68 17
PY2019 Principal investigator $33,029.40 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

137 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202535307
Principal investigator 1 ABBVIE INC. $1,226.14 12/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202528322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,196.20 12/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184269045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,072.46 11/20/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184263525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 11/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184261239
Principal investigator 1 ABBVIE INC. $34,076.90 11/13/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202524327
Principal investigator 1 ABBVIE INC. $6,943.35 11/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202523623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $555.75 11/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184258277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 11/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184258285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.00 11/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184258287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 11/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184258289
Principal investigator 1 ABBVIE INC. $10,641.80 11/05/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202521407
Principal investigator 1 ABBVIE INC. $8,238.10 10/23/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202518477
Principal investigator 1 Genentech, Inc. $42,542.00 10/22/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686416
Principal investigator 1 ABBVIE INC. $997.10 10/16/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202517393
Principal investigator 1 ABBVIE INC. $46,844.20 10/15/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202517061
Principal investigator 1 ABBVIE INC. $29,208.65 10/09/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202515917
Principal investigator 1 ABBVIE INC. $2,852.00 10/09/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202516489
Principal investigator 1 ABBVIE INC. $31,444.40 09/26/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202512534
Principal investigator 1 ABBVIE INC. $30,999.80 09/25/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202512446
Recipient Regeneron Pharmaceuticals, Inc. $211.54 09/12/2025 Covered Recipient Physician A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184119155
Principal investigator 1 ABBVIE INC. $1,800.00 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202508878
Principal investigator 1 ABBVIE INC. $13,270.26 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202508880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,778.75 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184235147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,970.00 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184235151
Principal investigator 1 ABBVIE INC. $10,050.30 09/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202507007
Principal investigator 1 Genentech, Inc. $16,881.00 09/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686288
Principal investigator 1 Genentech, Inc. $8,030.00 09/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686316
Principal investigator 1 Genentech, Inc. $1,523.00 09/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686324
Principal investigator 1 ABBVIE INC. $4,755.35 08/27/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202506017
Principal investigator 1 ABBVIE INC. $7,801.30 08/20/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202505291
Principal investigator 1 ABBVIE INC. $2,891.20 08/13/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202504513
Principal investigator 1 ABBVIE INC. $6,964.00 08/13/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202504519
Principal investigator 1 Exelixis Inc. $250.00 08/01/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,731.00 07/31/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184222796
Principal investigator 1 ABBVIE INC. $6,788.00 07/23/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202499332
Principal investigator 1 ABBVIE INC. $6,167.20 07/23/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202499406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114,751.03 07/22/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184217703
Principal investigator 1 ABBVIE INC. $7,801.30 07/16/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202498478
Principal investigator 1 ABBVIE INC. $7,159.10 07/16/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202498482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,069.10 07/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184214332
Principal investigator 1 ABBVIE INC. $2,891.20 07/09/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202497716
Principal investigator 1 Genentech, Inc. $365.00 07/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686320
Principal investigator 1 Genentech, Inc. $975.00 07/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686382
Principal investigator 1 Genentech, Inc. $10,979.00 07/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,961.68 07/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184213363
Principal investigator 1 ABBVIE INC. $16,039.40 06/20/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202492617
Principal investigator 1 ABBVIE INC. $9,114.30 06/13/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202491453
Principal investigator 1 Genentech, Inc. $600.00 06/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686206
Principal investigator 1 Genentech, Inc. $1,200.00 06/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686248
Principal investigator 1 Genentech, Inc. $2,490.00 06/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686256
Principal investigator 1 Genentech, Inc. $1,788.00 06/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686192
Principal investigator 1 ABBVIE INC. $28,715.00 06/03/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3) No dispute reported 06/30/2026 1202489033
Principal investigator 1 ABBVIE INC. $4,376.00 06/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202487303
Principal investigator 1 ABBVIE INC. $16,151.20 06/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202487305
Principal investigator 1 ABBVIE INC. $54.60 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202486547
Principal investigator 1 ABBVIE INC. $7,801.30 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202486549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184198817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184198819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184198821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 05/28/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184198823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,200.00 05/15/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184194597
Principal investigator 1 Genentech, Inc. $8,030.00 05/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686238
Principal investigator 1 Genentech, Inc. $1,095.00 05/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686280
Principal investigator 1 Exelixis Inc. $1,800.00 04/23/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386960
Principal investigator 1 ABBVIE INC. $3,681.60 04/18/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202478137
Principal investigator 1 Genentech, Inc. $1,825.00 04/18/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686218
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209749
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209751
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209753
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209755
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209757
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209759
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209761
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209763
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209765
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209767
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209769
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209771
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209773
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209775
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209777
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209779
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209781
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $250.00 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209783
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209785
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209787
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209789
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209791
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209793
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,730.30 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209795
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,787.50 04/17/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209797
Principal investigator 1 Exelixis Inc. $250.00 04/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386964
Principal investigator 1 ABBVIE INC. $7,976.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202474510
Principal investigator 1 ABBVIE INC. $1,200.00 04/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202468515
Principal investigator 1 Genentech, Inc. $73,112.00 04/02/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $316.00 04/01/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184180588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,478.00 03/25/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184178780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,730.00 03/25/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184178786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,037.00 03/19/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184174398
Principal investigator 1 Exelixis Inc. $2,535.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386912
Principal investigator 1 Exelixis Inc. $1,950.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386914
Principal investigator 1 Exelixis Inc. $1,170.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386916
Principal investigator 1 Exelixis Inc. $3,900.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386918
Principal investigator 1 Exelixis Inc. $19,500.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386920
Principal investigator 1 Exelixis Inc. $4,615.00 03/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors No dispute reported 06/30/2026 1222386922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,979.34 03/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184170748
Principal investigator 1 Genentech, Inc. $3,375.00 03/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Ph1 Solid Tumor Dose Escalation and Exploratory Cohorts No dispute reported 06/30/2026 1211686106
Principal investigator 1 Genentech, Inc. $5,000.00 03/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Ph1 Solid Tumor Dose Escalation and Exploratory Cohorts No dispute reported 06/30/2026 1211686116
Principal investigator 1 Genentech, Inc. $2,500.00 03/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Ph1 Solid Tumor Dose Escalation and Exploratory Cohorts No dispute reported 06/30/2026 1211686120
Principal investigator 1 Genentech, Inc. $7,800.00 03/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Ph1 Solid Tumor Dose Escalation and Exploratory Cohorts No dispute reported 06/30/2026 1211686136
Principal investigator 1 Genentech, Inc. $19,500.00 03/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
Ph1 Solid Tumor Dose Escalation and Exploratory Cohorts No dispute reported 06/30/2026 1211686160
Recipient Regeneron Pharmaceuticals, Inc. $103.10 03/04/2025 Covered Recipient Physician A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184119153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,430.00 03/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184156604
Principal investigator 1 Genentech, Inc. $8,405.00 02/26/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686108
Principal investigator 1 Genentech, Inc. $8,030.00 02/26/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686134
Principal investigator 1 Genentech, Inc. $338.00 02/26/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686138
Principal investigator 1 Genentech, Inc. $263.00 02/26/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686162
Principal investigator 1 Genentech, Inc. $260.00 02/21/2025 Non-covered Recipient Entity
YALE UNIVERSITY
GDC 2992 Ph1 in mCRPC No dispute reported 06/30/2026 1211686158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $370.00 02/20/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184155030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,127.00 02/18/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184154644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.29 02/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184153168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 02/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184153170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 02/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184153172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.00 02/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184153174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $593.00 02/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184153176
Principal investigator 1 Exelixis Inc. $3,900.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386924
Principal investigator 1 Exelixis Inc. $2,448.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386926
Principal investigator 1 Exelixis Inc. $3,900.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386928
Principal investigator 1 Exelixis Inc. $1,300.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386930
Principal investigator 1 Exelixis Inc. $3,900.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386932
Principal investigator 1 Exelixis Inc. $3,250.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386934
Principal investigator 1 Exelixis Inc. $3,900.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386936
Principal investigator 1 Exelixis Inc. $447.00 02/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386938
Principal investigator 1 ABBVIE INC. $1,800.00 01/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202438012
Principal investigator 1 ABBVIE INC. $6,164.00 01/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202438016
Principal investigator 1 AstraZeneca Pharmaceuticals LP $132,600.39 01/08/2025 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE DEPARTMENT OF ORTHOPAEDICS AMD REHABILITATION
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185551605